Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

Author(s): Kevin Kalinsky, MD, MS, FASCO¹; Giampaolo Bianchini, MD²; Erika Hamilton, MD³; Stephanie L. Graff, MD⁴; Kyong Hwa Park, MD, PhD⁵; Rinath Jeselsohn, MD⁶; Umut Demirci, MD, PhD⁷; Miguel Martin, MD, PhD⁸; Rachel M. Layman, MD⁹; Sara A. Hurvitz, MD¹⁰; Sarah Sammons, MD⁶; Peter A. Kaufman, MD¹¹; Montserrat Muñoz, MD¹²; Jiun-I Lai, MD, PhD¹³; Holly Knoderer, MD, MBA, MSc¹⁴; Cynthia Sandoval, PhD¹⁴; Aarti R. Chawla, PhD¹⁴; Bastien Nguyen, PhD¹⁴; Yanhong Zhou, PhD¹⁴; Elizabeth Ravenberg, PhD¹⁴; Lacey M. Litchfield, PhD¹⁴; Lillian Smyth, MD¹⁴; Seth A. Wander, MD, PhD¹⁵;

Source: https://doi.org/10.1200/JCO-24-02086

Dr. Anjan Patel's Thoughts

Yet another combination to consider after CDK4/6i + ET in HR+ MBC!

PURPOSE

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein, we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i.

METHODS

This double-blind, randomized phase III study enrolled patients with disease progression on previous CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i + ET. Patients were randomly assigned (1:1) to abemaciclib + fulvestrant or placebo + fulvestrant. The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included PFS by blinded independent central review, objective response rate (ORR), and safety.

RESULTS

This study randomly assigned 368 patients (abemaciclib + fulvestrant, n = 182; placebo + fulvestrant, n = 186). At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001). A consistent treatment effect was seen across major clinical and genomic subgroups, including with/without ESR1 or PIK3CA mutations. Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015). No new safety signals were observed, with findings consistent with the known safety profile of abemaciclib.

CONCLUSION

Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2– ABC, offering an additional targeted therapy option for these patients.

Author Affiliations

¹Winship Cancer Institute at Emory University, Atlanta, GA; ²IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy; ³Sarah Cannon Research Institute, Nashville, TN; ⁴Brown University Health, Legorreta Cancer Center at Brown University, Providence, RI; ⁵Korea University Anam Hospital, Korea University, Seoul, South Korea; ⁶Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; ⁷Memorial Ankara Hospital, Ankara, Turkey; ⁸Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain; ⁹MD Anderson Cancer Center, University of Texas, Houston, TX; ¹⁰Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, WA; ¹¹University of Vermont Medical Center, Burlington, VT; ¹²Hospital Clinic and Translational Genomics and Targeted Therapeutics, Institut d’Investigacions Biomediques Pi I Sunyer-IDIBAPS, Barcelona, Spain; ¹³Taipei Veterans General Hospital, Taipei, Taiwan; ¹⁴Eli Lilly and Company, Indianapolis, IN; ¹⁵Massachusetts General Hospital, Harvard University, Boston, MA;

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

The WSG-KEYRICHED-1 phase II trial evaluated a chemotherapy-free neoadjuvant regimen of pembrolizumab plus trastuzumab and pertuzumab in HER2-enriched early breast cancer, achieving a pathological complete response (pCR) rate of 46.5% (95% CI 31.2–62.6%). No survival data (e.g., EFS or OS) were reported, but the regimen showed an acceptable safety profile with no new cardiac toxicity signals. The chemo-free approach suggests promising potential for de-escalation in this subtype, but we’ll need randomized trials to confirm its efficacy and safety.

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

The INAVO120 trial assessed inavolisib + palbociclib–fulvestrant vs placebo plus palbociclib–fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, showing significant improvements in progression-free survival (PFS) (15.0 vs 7.3 months) and overall survival (OS) (34.0 vs 27.0 months). The triplet regimen achieved a higher overall response rate (ORR) (62.7% vs 28.0%), establishing it as a potential new standard for this endocrine-resistant population. Notably, side effects like hyperglycemia, stomatitis, diarrhea, and ocular effects were more frequent with inavolisib.

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial

Metronomic dose: low dose cytotoxic therapy at high frequency was studied in combination with an AI (cape at 500mg TID) and showed superiority over AI single agent, this may be an option for patients not tolerating CKD4/6 inhibitors.

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

In summary: It did not work in those patients with stages II-III.

Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial

The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.